Download MendeleyDiscovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.
Scott, J.D., DeMong, D.E., Greshock, T.J., Basu, K., Dai, X., Harris, J., Hruza, A., Li, S.W., Lin, S.I., Liu, H., Macala, M.K., Hu, Z., Mei, H., Zhang, H., Walsh, P., Poirier, M., Shi, Z.C., Xiao, L., Agnihotri, G., Baptista, M.A., Columbus, J., Fell, M.J., Hyde, L.A., Kuvelkar, R., Lin, Y., Mirescu, C., Morrow, J.A., Yin, Z., Zhang, X., Zhou, X., Chang, R.K., Embrey, M.W., Sanders, J.M., Tiscia, H.E., Drolet, R.E., Kern, J.T., Sur, S.M., Renger, J.J., Bilodeau, M.T., Kennedy, M.E., Parker, E.M., Stamford, A.W., Nargund, R., McCauley, J.A., Miller, M.W.(2017) J Med Chem 60: 2983-2992
- PubMed: 28245354
- DOI: https://doi.org/10.1021/acs.jmedchem.7b00045
- Primary Citation of Related Structures:
5U6I - PubMed Abstract:
Leucine-rich repeat kinase 2 (LRRK2) is a large, multidomain protein which contains a kinase domain and GTPase domain among other regions. Individuals possessing gain of function mutations in the kinase domain such as the most prevalent G2019S mutation have been associated with an increased risk for the development of Parkinson's disease (PD). Given this genetic validation for inhibition of LRRK2 kinase activity as a potential means of affecting disease progression, our team set out to develop LRRK2 inhibitors to test this hypothesis. A high throughput screen of our compound collection afforded a number of promising indazole leads which were truncated in order to identify a minimum pharmacophore. Further optimization of these indazoles led to the development of MLi-2 (1): a potent, highly selective, orally available, brain-penetrant inhibitor of LRRK2.
Organizational Affiliation:
Merck & Co., Inc. , 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States.
